Precigen, Inc. Common Stock
PGEN Real Time Price USDRecent trades of PGEN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PGEN's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Molecular switches Sep. 17, 2024
-
Patent Title: Expression of novel cell tags Aug. 13, 2024
-
Patent Title: Methods and microorganisms for making 1,4-butanediol and derivatives thereof from c1 carbons Jun. 25, 2024
-
Patent Title: Frataxin expression constructs Jun. 04, 2024
-
Patent Title: Muc16 specific chimeric antigen receptors and uses thereof May. 14, 2024
-
Patent Title: Muc16 specific chimeric antigen receptors and uses thereof May. 07, 2024
-
Patent Title: Modulating expression of polypeptides via new gene switch expression systems Apr. 02, 2024
-
Patent Title: Methods and microorganisms for making 2,3-butanediol and derivatives thereof from c1 carbons Mar. 26, 2024
-
Patent Title: Biological production of multi-carbon compounds from methane Nov. 21, 2023
-
Patent Title: Cd33 specific chimeric antigen receptors Oct. 17, 2023
-
Patent Title: Polypeptide compositions comprising spacers Oct. 03, 2023
-
Patent Title: Modulating expression of polypeptides via new gene switch expression systems Jul. 04, 2023
-
Patent Title: Hepatitis b vaccines and uses of the same Mar. 21, 2023
-
Patent Title: Fusion constructs and methods of using thereof Dec. 27, 2022
-
Patent Title: Methods and microorganisms for the fermentation of methane to multi-carbon compounds Aug. 23, 2022
-
Patent Title: Muc16 specific chimeric antigen receptors and uses thereof May. 03, 2022
-
Patent Title: Molecular switches Dec. 14, 2021
-
Patent Title: Methods and microorganisms for making 1,4-butanediol and derivatives thereof from c1 carbons Oct. 26, 2021
-
Patent Title: Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies Oct. 26, 2021
-
Patent Title: Expression of novel cell tags Sep. 14, 2021
-
Patent Title: Frataxin expression constructs Sep. 14, 2021
-
Patent Title: Methods and microorganisms for making 2,3-butanediol and derivatives thereof from c1 carbons Sep. 07, 2021
-
Patent Title: Expression of novel cell tags Jun. 15, 2021
-
Patent Title: Biological production of multi-carbon compounds from methane Dec. 29, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of PGEN in WallStreetBets Daily Discussion
Recent insights relating to PGEN
Recent picks made for PGEN stock on CNBC
ETFs with the largest estimated holdings in PGEN
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.